Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-PRF With or Without Chlorhexidine in Stage III Periodontitis
NCT07791238Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Sponsor
- Cairo University
- Conditions
- periodontitis
01
Overview
Phase 2, randomised trial of injectable platelet-rich fibrin and chlorhexidine + cymenol gel in periodontitis (3 arms), sponsored by Cairo University. Primary endpoint: Probing Depth Reduction at 6 months. Planned start Sep 2026; status: not yet recruiting.
02
Design
3 arms- Study design
- Randomized
MINST alone
Minimally Invasive Nonsurgical Therapy alone
MINST + I-PRF alone
MINST combined with Injectable Platelet-Rich Fibrin
MINST + I-PRF + CHX
MINST combined with Injectable Platelet-Rich Fibrin and Chlorhexidine 2%
03
Who it enrols
Adult patients with untreated stage III periodontitis (grade A/B) with specific intrabony defects and pocket depths, excluding heavy smokers, pregnant/nursing women, and those with recent periodontal or antibiotic treatments.
04
Endpoints
Primary
Probing Depth Reduction
Secondary
Clinical Attachment Level
Gingival Recessions
Biochemical marker levels in GCF samples (TNF-α, IL-1β and IL-10 levels)
Patient Reported Outcomes
Perceived Post-operative Pain/Discomfort
Radiographic Linear Defect Depth
Plaque Index
Bleeding on Probing
Beyond the preview
Go deeper on NCT07791238.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791238.